Defamation suit brought by doc who performed unnecesary stentings tossed; Study: Device industry held in higher esteem than pharma;

@FierceMedDev: Orthofix to sell sports-medicine unit for $157.5M - MarketWatch. Report | Follow @FierceMedDev

> A Baltimore County judge has dismissed a defamation lawsuit filed by Dr. Mark Midei against St. Joseph Medical Center. Midei is embroiled in a scandal over performing unnecessary heart stent procedures. Report

> Patient groups tend to look favorably upon the global device industry, with 52% in a study funded by PatientView giving it a "good" or "excellent" corporate reputation. Only 40% held similar views about the pharma industry. Item

> Xinhua is reporting that EU health ministers will establish a special committee to take action against faulty medical devices on the European market. Danish Health Minister Astrid Krag reportedly made those comments during an informal meeting of health ministers. Item

> LDR has received 510(k) clearance from the FDA to market the ROI-C Lordotic cervical cage. The company makes spinal implants for both non-fusion and fusion applications. LDR release

> BVF Partners is looking to resurrect shareholder claims in a class action over Quest Diagnostics' purchase of Celera. The private equity firm held a 24% stake in Celera before the merger. Story (sub. req.)

Biotech News

 @FierceBiotech: Biogen Idec builds blockbuster case for new MS drug BG-12. Article | Follow @FierceBiotech

 @JohnCFierce: Another interesting tidbit in Merck KGaA PR: It's committing up to $40 million to provide seed funding for spinoffs as they downsize. | Follow @JohnCFierce

 @RyanMFierce: Here in Boston for Bio-IT World Conference & Expo 2012, will keep you guys updated on what I learn about the tech/IT side of the biotech world this week. | Follow @RyanMFierce

> Analysts buzz over new Amgen CEO's plans for $20B cache. Article

> Merck KGaA shuttering Swiss complex, dispersing R&D staffers to Boston and Beijing. News

>  AstraZeneca plots more pipeline deals. Spotlight

Pharma News

 @FiercePharma: More on Novartis' Q2 results, from Bloomberg. Consumer sales tumble 20% on plant closure. Article | Follow @FiercePharma

> Merck Serono to cut 580 Swiss jobs, close Geneva HQ. News

> Watson set to unveil $5.9B Actavis buy, FT reports. Article

> Novartis wants UK to quash off-label Avastin use. Story

Biotech Research News

> Powerful protein halts DNA damage and may block tumors. News

> Johns Hopkins researchers find gene tied to CF secondary complication. Article

> Swedish scientists identify stem cells that form new brain material. Story

Pharma Manufacturing News

> China seizes 77 million tainted drug capsules in crackdown. Spotlight

> Merck KGaA manufacturing dodges worst of reductions. News

> Pfizer, J&J, Abbott facing shortages of crucial ingredients in Pakistan. Article

And Finally... Astronauts endure a lot during space flights, including the potential for health risks. The high costs of taking care of them in space necessitate NASA's need for low-cost, simple medical devices. And some are already looking to improve the situation. News

Suggested Articles

Takeda tapped Roche’s Foundation Medicine to develop tissue- and blood-based companion diagnostic tests for its portfolio of lung cancer therapies.

Cellex has announced plans to develop a rapid coronavirus test that people can fully perform at home, from sample collection to result, using an app.

More than 20 states either don’t release or have incomplete data on the rapid antigen tests now considered key to containing the coronavirus.